Search Results

Join NCF for Jan2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Q3ji1Zdo9oE ABOUT Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. ABOUT DR. METZ David Metz, MD Gastroenterologist University of Pennsylvania School of Medicine Retired Professor CE of Medicine, Perelman School of Medicine, Co-director, GI Physiology Laboratory, Director, Acid Peptic Disorders Specialty Program, Co-director, Penn Program for Swallowing Disorders, Associate Chief for Clinical Affairs, Division of Gastroenterology, Co-director, University of Pennsylvania Neuroendocrine Tumor Program After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. RESOURCES Listen Read Our Cancer Stories: "Understanding Gastric Neuroendocrine Tumors" "Stages of Gastric Neuroendocrine Tumors" "Hormone Therapy for Gastric Neuroendocrine Tumors" "Types and Grades of Gastric Neuroendocrine Tumors" The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Join NCF for Jan2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Vb7aH06UWrE Download PowerPoint Slides >>> Some Topics Covered: Types of Functional Neuroendocrine Tumors, Hormone-producing, Carcinoid Syndrome, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Diarrhea, Flushing, Hypoglycemia, Carcinoid Heart Disease, Cushing Syndrome, Somatostatinoma. ABOUT Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. THANKS TO OUR SPONSORS PRESENTING SPONSOR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC << Back A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab IDENTIFIER ( ClinicalTrials.gov ) : NCT05142696 DRUG/TREATMENT : LUTATHERA (Lu-177 Dotatate) + Carboplatin, Etoposide, and Atezolizumab PHASE : 1b / 2 STATUS : Recruiting SPONSOR : Novartis Pharmaceuticals DESCRIPTION: https://www.youtube.com/watch?v=0h8ye62LDT0 Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC ." Recorded: June 20, 2024 This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Novartis Pharmaceuticals EMAIL: novartis.email@novartis.com PHONE: 1-888-669-6682 RELATED RESOURCES : Clinical Trials Using Lutetium Lu 177 Dotatate - NCI https://www.youtube.com/watch?v=oCHpfmQLeJM "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD

<< Go back to the Podcast page EPISODE 52 - Spotlight on Genetic Counselors Download a Transcript of this Episode >>> ABOUT THIS EPISODE Who is a genetic counselor, and who should see one? How do they fit into the neuroendocrine cancer care team? In this episode, Samantha Greenberg, PhD, MS, MPH, CGC, Director of the UT Southwestern Genetic Counseling Program, demystifies genetic counseling and testing for NET patients and their families. She explains what to expect before, during, and after a consultation—and how results can impact care, family members, and future planning. TOP TEN QUESTIONS Role & Training 1. What is a genetic counselor? What training is required? What’s your role in the care team? Genetic Counseling & NETs 2. How are genetic counselors involved in NET care? 3. Who should get genetic testing? Do all NET patients need it? What if more than one family member has NET? Do you also see family members without a diagnosis? 4. How does one’s age play a role? Testing Basics 5. Genetic vs. genomic vs. NGS—what are these terms? How do patients know they’re getting the right test? 6. Walk us through a genetic counseling consultation—before, during, after. Results & Implications 7. What if the results are positive? How do you guide patients and families? What if the results are negative or inconclusive? How accurate are tests? 8. What is a “variant of unknown significance”?9. Can environment or toxins cause hereditary mutations? Practical Guidance 10. How can patients find the right genetic counselor? Do they need to be someone who specializes in neuroendocrine cancer? MEET SAMANTHA GREENBERG Samantha Greenberg, PhD, MS, MPH, CGC Pronouns: she/her Director, UT Southwestern Genetic Counseling Program Assistant Professor School of Health Professions Samantha Greenberg is the founding program director of the UT Southwestern Genetic Counseling Training Program. She received her Master of Science degree in genetic counseling and public health from the University of Michigan after teaching middle school science with Teach For America in Tulsa, Oklahoma. She recently completed her Ph.D. at the University of Utah. As a cancer genetic counselor, Greenberg has provided clinical care across a variety of indications and facilitated the development of multidisciplinary teams and genetics clinics for patients with prostate cancer, von Hippel-Lindau syndrome, and paraganglioma/pheochromocytoma. She is the co-director of the paraganglioma program at UT Southwestern, which recently received a Center of Excellence designation from Pheo Para Alliance. Her passion for raising awareness on the genetics of neuroendocrine tumors stems from working with patients and a curiosity for how to optimize identification of patients with hereditary risk. RESOURCES Watch https://www.youtube.com/watch?v=VWMdD5LJAFo Genetics of NET: Do I Need Genetic Testing with Samantha Greenberg (Feb 2023) https://www.youtube.com/watch?v=wgEoFAQ7lp8 Deciphering Genetics & Genomics in Neuroendocrine Cancers with Dr. Kimberly Perez (Feb 2025) EXPLORE FindaGeneticCounselor.com https://pheopara.org/ DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC << Back A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy IDENTIFIER ( ClinicalTrials.gov ) : NCT06736418 DRUG/TREATMENT : 225Ac-ABD147 PHASE : 1A/B STATUS : Recruiting SPONSOR : A bdera Therapeutics Inc. https://www.youtube.com/watch?v=PDR0flgpAXE DLL-3-RLT Presentation Slides .pdf Download PDF • 863KB DESCRIPTION: This is an open-label, Phase 1a/1b, first-in-human study testing a new targeted treatment called 225Ac-ABD147 for people with locally advanced or metastatic small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung. All participants must have previously received platinum-based chemotherapy. What is 225Ac-ABD147? 225Ac-ABD147 is a DLL3-targeting antibody fragment, a small, engineered piece of an antibody that targets cancer cells with a marker called delta-like ligand 3 (DLL3) . It is attached to a special linker-chelator that holds a radioactive particle ( Actinium-225 ) so that a precise dose of radiation can be delivered directly to DLL3-positive cancer cells. The study has two parts: Phase 1a and Phase 1b . Phase 1a: Safety, Dosing & Early Signals Phase 1a is designed to understand: Safety and side effects How the drug moves through the body (PK and biodistribution) Early signs of effectiveness The safest and most appropriate dose levels A small group of participants will also receive an experimental imaging agent, 111In-ABD147 , to help researchers see how the treatment travels and where it binds in the body. Phase 1b: Expanded Testing at Selected Doses Phase 1b uses the dose levels identified in Phase 1a to further evaluate: Safety How well the treatment works for SCLC and LCNEC This phase helps researchers better understand the potential benefit of 225Ac-ABD147 in these cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Abdera Therapeutics Inc. EMAIL: AbderaClinicalTrials@abderatx.com PHONE: 1 650-434-4093 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Lu-177 DOTATATE + Olaparib in GEP-NETs << Back Lu-177-DOTATATE in Combination With Olaparib in Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) CLINICALTRIALS.GOV IDENTIFIER: NCT04086485 DRUG/TREATMENT: Lu-177 DOTATATE + OLAPARIB PHASE I / II STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=CC2NXP21R24 Dr. Del Rivero discusses Lu177-Dotatate + OLAPARIB DESCRIPTION: This phase 1-2 trial tests Lu-177-DOTATATE (Lutathera) in combination With olaparib (PARP inhibitor) in inoperable gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). The objective is to learn if people with certain neuroendocrine tumors can take a combination of 2 drugs, Lu-177 DOTATATE and Olaparib, without having severe side effects, and if this treatment makes the tumors shrink. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Frank Lin, MD CONTACT: National Cancer Institute Joy Zou, RN EMAIL: joy.zou@nih.gov PHONE: 240-760-6153

<< Back NIH/NCI Natural History Study for Neuroendocrine Neoplasms Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Join NCF for July2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=iTlGH2gbmcE ABOUT Caregivers share their experiences supporting a loved one with neuroendocrine cancer, including navigating treatment decisions, managing uncertainty, balancing caregiving responsibilities, and caring for themselves along the way. Through candid conversations about challenges, lessons learned, relationships, resilience, and hope, this session offers valuable insight into the realities of the caregiving journey. Interested in hearing the patient perspective as well? View our July 2025 webinar, Living with NET: The Patient Perspective: Living with NET: The Patient Perspective . SPEAKERS ALYSE KEFELI Caregiver Alyse Kefeli lives in Rhode Island with her husband and works as an Information Technology Program Manager in the financial industry. She enjoys gardening, cooking, biking, playing pickleball, walking by the ocean, and spending time with family. She is also active in her faith and values the sense of community and support it provides. Alyse's daughter, Serra, was diagnosed with a metastatic neuroendocrine tumor (NET) that originated in the small bowel at just 32 years old. Since then, Alyse has supported Serra through two major surgeries, ongoing treatment, and the many emotional and practical challenges that come with living with NET. Along the way, she has found strength through education, faith, and connecting with other caregivers. Alyse is a member of the Neuroendocrine Cancer Foundation's monthly Caregiver Support Group, where she meets with fellow caregivers to share experiences, learn from one another, and offer mutual encouragement. She hopes that sharing her family's journey will help other caregivers feel less alone, better informed, and more hopeful as they navigate life with NET. Patient & Caregiver Journey - Sara & Quintin CYNTHIA MUELLER CROCKER Caregiver Cynthia Mueller Crocker lives in Houston with her husband, Charlie, where they gladly trade icy winters for Texas heat and humidity. After caring for and advocating for both of her aging parents, Cynthia stepped into Charlie’s NET journey with compassion and hard-earned perspective. While neuroendocrine cancer was new to her, she found education, connection, and support through LACNETS, now NCF, in 2020 and has been an active part of its weekly support groups and monthly caregiver groups ever since. Her professional background is in organization and talent development, where she has found great satisfaction in recognizing potential, identifying opportunities, and creating strategies to support the success of organizations, teams, and individuals. Charlie and Cynthia share a love of college football and happily count football season as “the best time of the year,” especially when cheering on Charlie’s Crimson Tide and Cynthia’s beloved Texas Longhorns. But their favorite seats in the bleachers is the front row cheering section as they watch their large, coast-to-coast family grow and thrive! SHANE PETERS Caregiver and Advocate Shane has been walking alongside his mother through her neuroendocrine cancer journey that started in 2020 with a diagnosis of stage four pancreatic neuroendocrine tumor that had already spread to the liver. Shane hopes to continue to give back to the NET community by sharing all he’s learned through his mother’s experiences with lanreotide, surgeries, embolizations and PRRT. Watch "The Strength of Support: the Shane and Ilka Peters Story." Watch Shane and his mother share their NET journey. Read Shane Peters' blog post 'Scan Results: To Check or Not to Check' MODERATOR: HEATHER DAVIS Director of Community Engagement Heather was a medical advocate and caregiver for 12 years for her mother, Shaunie, who was diagnosed with pancreatic neuroendocrine cancer in 2012. The efforts required to navigate and manage a rare disease, with complications of Zollinger-Ellison Syndrome, motivated Heather to shift her 20-year marketing career to patient engagement. After learning from and volunteering for LACNETS, she was pleased to join the LACNETS Team in the Fall of 2022. Heather is passionate about supporting those affected by NET. She aspires to bridge the information gap between patients, physicians and healthcare resources. Spending time with her nephews, friends & family brings her levity and joy. Watch Heather and her mother share about their experience with PRRT. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

< Go Back to the Resource Guide CARCINOID HEART DISEASE WATCH https://www.youtube.com/watch?v=jU1HE38G8JQ Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. https://www.youtube.com/watch?v=DcewKhYm8uY Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. https://www.youtube.com/watch?v=Y5PGL8-kFR4 Guests: Juan A. Crestanello, MD and Thor R. Halfdanarson, MD Host: S. Allen Luis, MBBS, PhD Join Mayo Clinic Cardiologist S. Allen Luis, M.B.B.S., Ph.D., surgeon Juan A. Crestanello, M.D. and oncologist Thor R. Halfdanarson, M.D. for up-to-date knowledge and information on Carcinoid Heart Disease. Recognize the natural history of patients with carcinoid heart disease. Identify treatment strategies for patients with metastatic neuroendocrine tumors and its impact on the heart Identify the medical and surgical treatment of patients with carcinoid heart disease. PATIENT STORIES https://www.youtube.com/watch?v=4TU4WMGd4lc Watch Jesse & Ellen share their story of living with Carcinoid Heart Disease. https://www.youtube.com/watch?list=PLPAgUIq-85n9gMW_Majhts3lqzoIaIQbx&v=tMBDhGT5lmI Watch Gwendolyn’s story of living with metastatic NET and Carcinoid Heart Disease. LISTEN What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD? Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview of CHD and describes the appropriate screening, diagnosis, and treatment. Visit the Podcast Episode 43 webpage for more information and resources. READ Davar et al (2017). "Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement". J Am Coll Cardiol.; 69 (10) 1288–1304 Jin et al (2021). "Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management". Cardiology;146:65–73 Ram et al (2019). "Carcinoid Heart Disease:Review of Current Knowledge". Texas Heart Institute Journal February 2019, Vol. 46, No. 1

ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs << Back Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu-177 Dotatate in Patients with Advanced Pancreatic Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT05247905 DRUG/TREATMENT: Lutetium Lu-177 Dotatate PRRT (Peptide Receptor Radionuclide Therapy) versus CAPTEM (Capecitabine and Temozolomide) PHASE: 2 STATUS: Closed SPONSOR: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) https://www.youtube.com/watch?v=jEO6in8giTk Dr. Heloisa Soares Discusses ComPareNET: Lu-177 DOTATATE vs CAPTEM DESCRIPTION: This phase II trial compares capecitabine and temozolomide to lutetium Lu-177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. The purpose of this study is to find out whether capecitabine and temozolomide or lutetium Lu-177 dotatate may kill more tumor cells in patients with advanced pancreatic neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Go Back to NCF Events Page “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — who present on topics relevant to neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join with their lunch break. Live sessions are recorded and will be available afterwards. ABOUT BORIS G. NARAEV, MD, PHD, FACP Dr. Naraev is a board-certified medical oncologist at the Tampa General Hospital’s Cancer Institute specializing in caring for people living with neuroendocrine and endocrine tumors. He is an Associate Professor of Medicine at the Division of Hematology and Medical Oncology of University of South Florida, Morsani College of Medicine. Prior to joining the TGH Cancer Institute, he was the Lead of Neuroendocrine Cancer Program at Banner MD Anderson Cancer Center in Phoenix, Arizona and Adjunct Assistant Professor with the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. While in Phoenix, he helped create, develop, and lead one of the largest neuroendocrine cancer programs in the Southwestern United States, and was personally taking care of a large population of patients with neuroendocrine tumors. Later, he served as the Leader of Gastrointestinal, Neuroendocrine, and Rare Cancers Program at the Anderson Family Cancer Institute at Jupiter Medical Center in Jupiter, Florida. In this capacity, he helped build the National Pancreas Foundation Pancreatic Cancer Center of Excellence at Jupiter Medical Center. He received his Doctor of Medicine degree from Orenburg State Medical Academy in Orenburg, Russia. Subsequently, he obtained a PhD in Medical Sciences degree from the same institution. After completion of Internal Medicine residency training at St. Luke's Hospital in Chesterfield, Missouri, he proceeded to complete Hematology/Oncology Fellowship at the University of Iowa Hospitals and Clinics in Iowa City, Iowa. During his fellowship training, he developed a special interest in neuroendocrine tumors and completed several research projects in this field. Dr. Naraev is involved in neuroendocrine tumors related research and community outreach, and is a member of the NETPact Committee and Chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS). Dr. Naraev also serves as a member of the National Cancer Institute’s Neuroendocrine Tumors Task Force. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

Join NCF for Arizona. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/playlist?feature=share&list=PLPAgUIq-85n87MCeOUD77oRr6XQYk-mrG ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. Hear presentations from 8 NET experts. Listen to patient stories. Learn about the latest in surgery, liver-directed therapy, systemic therapy, PRRT, and clinical trials. Ask questions during the extended live question and answer session. Find out how you can spread awareness about neuroendocrine cancer. Network with other patients and caregivers in the post-event reception. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Junaid Arshad, University of Arizona Cancer Center (UACC). This event will not be broadcast. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 1:30 - 2 PM Check-in 2 - 2:10 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 2:10 - 2:15 PM Patient Story Kimberly, NET Patient 2:15 - 2:30 PM NETs 101: NET Terms & Concepts You Need to Know Bassam Sonbol, MD, Medical Oncologist, Mayo Clinic Phoenix 2:30 - 2:45 PM Surgery for NETs: To Cut or Not to Cut? Gagandeep Singh, MD, Surgical Oncologist, City of Hope Phoenix 2:45 - 3 PM Liver-Directed Therapy: Killing Liver Tumors Without a Big Scar Gregory Woodhead, MD, PhD, Interventional Radiologist, University of Arizona Cancer Center 3 - 3:15 PM Systemic Therapy for NETs: Treatment Options for Metastatic Tumors Heloisa Soares, MD, PhD, Medical Oncologist, Huntsman Cancer Institute 3:15 - 3:30 PM PRRT: Current & New Trends Holly Thompson, MD, MPH, Nuclear Medicine, University of Arizona Cancer Center 3:30 - 3:45 PM Break 3:45 - 3:50 PM Nursing Perspective on the Management of NETs Linda Moe, RN, University of Arizona Cancer Center 3:50 - 4:05 PM Clinical Trials: The Latest & Greatest Pamela Kunz, MD, Medical Oncologist, Yale Cancer Center 4:05 - 5 PM Q&A with Expert Panel All Faculty - Moderated by Dr. Junaid Arshad, Medical Oncologist, University of Arizona Cancer Center & Lisa Yen, LACNETS 5 - 6 PM Networking Reception ABOUT OUR SPEAKERS Dr. Junaid Arshad Medical Oncologist, University of Arizona Cancer Center (UACC) Host/Moderator/Speaker Dr. Junaid Arshad is an Assistant Professor of Medicine and our new faculty member of GI Medical Oncology. He received his medical degree from King Edward Medical University, Lahore, Pakistan. He completed his Internal Medicine Residency at St. Mary's Hospital, Waterbury, CT. He has joined the Cancer Center after his Hematology and Medical Oncology Fellowship from University of Miami, FL. Dr. Arshad is a Clinical and Translational Scientist with a focus on developing novel therapeutics for several areas of Upper GI Oncology. Dr. Arshad's Clinical and Research focus targets mainly the Upper GI Oncology including Gastrointestinal Stromal Tumors, Gastric Cancers, Esophageal Cancers and Neuroendocrine Tumors. He is a part of several clinical trials and has contributed to several peer reviewed publications. His prior research focuses on the use of biomarkers such as circulating tumor DNA (ctDNA) in the diagnosis, treatment and surveillance of Gastrointestinal Stromal Tumors. He has expanded his areas of research interest to include other disease modalities such as Neuroendocrine Cancers. Dr. Pamela Kunz Medical Oncologist, Yale Cancer Center Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including past President of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. Dr. Kunz was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021. Dr. Kunz was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity and received the 2024 'Distinguished Mentor Award' by the North American Neuroendocrine Tumor Society. X @PamelaKunzMD Linda Moe, RN Registered Nurse, University of Arizona Cancer Center (UACC) I have been an oncology nurse for 34 years, working in both inpatient and outpatient settings. My experiences range from bedside nursing, ambulatory care, ICU care, charge nurse, nurse manager, nurse navigator and RN coordinator. Currently, I am working as Dr. Arshad’s RN coordinator. I have been working specifically with GI cancers for the past seven years. I spearheaded and achieved NAPRC accreditation status at the University of Arizona Cancer Center. I have specialized in Bone Marrow Transplant, pain management, palliative care, wound care and end-of-life care. I hold a bachelor’s degree in nursing and a bachelor’s degree in naturopathy with an emphasis on wellness and cancer prevention. I am a Reiki Master with over 20 years of Reiki experience. I was selected as a “Fabulous 50” nurse in 2020 and successfully passed a law establishing “National Fatigue Awareness Day” in the state of Arkansas. Dr. Gagandeep Singh Surgical Oncologist, City of Hope Phoenix Internationally renowned liver and pancreas surgeon Gagandeep “Gaugs” Singh, M.D., F.A.C.S., is Chief of Surgical Oncology and Director of Surgical Services at City of Hope® Cancer Center Phoenix. A seasoned health care leader with more than 20 years’ experience building outstanding surgical teams, Dr. Singh is excited to return to Phoenix – where he completed part of his medical training – and to City of Hope, where he spent a decade as the chief of City of Hope Duarte’s surgical oncology program. In the clinic, Dr. Singh takes a thoughtful yet forceful approach to treating cancers of the liver, pancreas and gastrointestinal systems. As a health care leader, he is passionate about empowering teams to achieve their fullest potential. He has been recognized with numerous awards and leadership positions. After beginning his faculty academic career at the Keck School of Medicine at the University of Southern California in Los Angeles, Dr. Singh was appointed director of the Liver and Pancreas Center at the John Wayne Cancer Institute in Santa Monica, California, where he also served as chair of the Cancer Committee. At City of Hope Duarte, Dr. Singh spearheaded the liver and pancreatic cancer programs and led the Division of Surgical Oncology to national recognition. He has been included on multiple lists of “America’s Top Surgeons,” “Best Doctors of America,” “Super Doctors” and “Top Doctors of America.” Dr. Singh earned his medical degree from the Mahatma Gandhi Institute of Medical Sciences in India, before training at multiple internationally renowned cancer centers, including Tata Memorial Hospital and Cancer Center in Bombay, René Descartes University in Paris and the Royal Liverpool University Hospital in the United Kingdom, as well as the Marion Bessin Liver Center at the Albert Einstein College of Medicine in New York, Maricopa Medical Center in Phoenix and the University of Iowa. A board-certified surgeon, diplomate of the American Board of Surgery and fellow of the American College of Surgeons, Dr. Singh is an internationally recognized expert in his field and a member of the National Comprehensive Cancer Network for Hepatobiliary Cancers, the group that sets the guidelines for the standard of care for hepatobiliary cancers. As a researcher, Dr. Singh has written on topics such as complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions with difficult pancreatic surgery for pancreatic cancer and advanced robotic surgery. His work on robotic surgery has been presented at the Society of Surgical Oncology, America’s Hepato-Pancreato-Biliary Association, the Society of Laparoscopic & Robotic Surgeons and other national meetings. An innovator at heart, he is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborated with engineers from the California Institute of Technology and Harvey Mudd College and has several invention disclosures and patents to his name. Dr. Singh’s translational research includes projects with molecular biologists, X-ray crystallographers, structural chemists and super-resolution scientists across the City of Hope national system . Dr. Heloisa Soares Medical Oncologist, Huntsman Cancer Institute Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79 Dr. Bassam Sonbol Medical Oncologist, Mayo Clinic Phoenix Mohamad Bassam Sonbol, M.D., is an Oncologist, with special interest in neuroendocrine tumors and gastrointestinal malignancies. In addition to his clinical activities, Dr. Sonbol is active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents that could potentially help patients with neuroendocrine and gastrointestinal cancers. Dr. Sonbol focuses on the holistic treatment for cancer patients taking into consideration their medical and social aspects that have been affected by their cancer diagnosis. Dr. Holly Thompson Nuclear Medicine & Theranostics, University of Arizona Cancer Center (UACC) My passion for medicine is defined by a tenacious desire to diagnose and treat diseases that cause human suffering. Profoundly inspired by the study of cancer, I pursued research into its biology first working at the Fred Hutchinson Cancer Center and then related innovative imaging technologies working at Vitra Bioscience, following my undergraduate degree. Driven to help address cancer and other complex diseases at a more direct and personal level, I earned my Doctor of Medicine degree from the University of Miami, followed by a Masters in Public Health. After an internship in surgery at Harvard, I completed postgraduate Radiology training at UC Davis and further subspecialized in Nuclear Medicine training at Stanford University, where I learned about neuroendocrine tumors having witnessed NETTER-1 trial participants. I had the privilege of joining a large integrated healthcare provider in Northern California where I worked to enable NET patients’ early access to 177Lu-Dotatate(Lutathera, prior to FDA approval. Subsequently I became the Nuclear Medicine physician lead for regional multidisciplinary NET tumor boards facilitating patient cases to be rigorously reviewed with an integrated, patient-centered focus. Currently, as an Associate Professor at the University of Arizona, my focus is on advancing NET patient care and research, while teaching and inspiring the next generation of Nuclear Radiologist/Oncologist. It is an honor to be invited to participate in the LACNETS outreach program. Dr. Gregory Woodhead Interventional Radiology, University of Arizona Cancer Center (UACC) Gregory Woodhead, MD, PhD, joined the interventional radiology faculty at University of Arizona, with the majority of his practice focusing on interventional oncology at the University of Arizona Cancer Center. Dr. Woodhead’s career objective is to translate devices and therapies from the development stage into clinical practice. His interest in cancer cell biology draws from his PhD research on the role of the catenin-signaling pathway in cell fate decisions for progenitor and cancer cells. As a resident and fellow at the University of Arizona, he embarked on an analysis of catheter-directed mechanical thrombectomy for the treatment of acute pulmonary embolism (PE), which is a common cause of morbidity and mortality in cancer patients. He is the PI on multiple trials and registries that seek to identify long-term differences in patients who received mechanical thrombectomy for PE in comparison to those who received only anticoagulation alone. Dr. Woodhead has published over 40 papers and frequently presents at national and international meetings. He is an integral member of multiple institutional programs and a committee member for many professional societies. He is passionate about educating and mentoring medical students, residents, and fellows. He previously served as the chair of the MD/PhD admission committee.